PREPARATION OF HIGHLY PURIFIED SOLVENTDETERGENT COA GULATION FACTOR VII AND FACTOR IX CONCENTRATES FROM PROTHROMBIN COMPLEX (PPSB)
Authors
Abstract:
In this study, anion-exchange chromatography was used to purify factor VII and factor IX from prothrombin complex (PPSB), which contains coagulation factors II, VII, IX and X. For this purpose, DEAE-Sepharose CL-6B gel , Pharmacia column XK-26 , high flow rate and two stepwise gradients with phosphate citrate buffer were used. The yield of the two lyophylized products, factor VII and factor IX concentrates, was 61 % and 75%, respectively. Specific activity of factor VII increased from 0.16 to 3.06 (purification-fold= 19.1) and specific activity of factor IX increased from 12 to 4.9 (purification-fold= 4.1). Results of electrophoresis on agarose gel-as well as immunoelectrophoresis-indicated higher purity of factor VII and factor IX compared to PPSB. Thrombogenicity of the two products were within the normal range defined for PPSB. In order to improve viral safety, solvent-detergent treatment was performed prior to further purification. Factor VII concentrate is used for patients with factor VII deficiency and also for hemophilia patients with inhibitors. Factor IX concentrate is used for treatment of hemophilia B patients.
similar resources
preparation of highly purified solventdetergent coa gulation factor vii and factor ix concentrates from prothrombin complex (ppsb)
in this study, anion-exchange chromatography was used to purify factor vii and factor ix from prothrombin complex (ppsb), which contains coagulation factors ii, vii, ix and x. for this purpose, deae-sepharose cl-6b gel , pharmacia column xk-26 , high flow rate and two stepwise gradients with phosphate citrate buffer were used. the yield of the two lyophylized products, factor vii and factor ix ...
full text6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates
6.5 Range of Application, Dosage, Mode of Administration 6.5.1 General Information 6.5.2 Indications for Replacement Therapy Using Factor Concentrates 6.5.3 Dosage, Mode of Administration 6.5.3.1 Replacement in Children with Hemophilia A, B or von Willebrand Syndrome 6.5.3.2 Replacement in Adults with Hemophilia A, B or von Willebrand Syndrome 6.5.3.3 Indications and Recommended Doses for Treat...
full text6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.
6.5 Range of Application, Dosage, Mode of Administration 6.5.1 General Information 6.5.2 Indications for Replacement Therapy Using Factor Concentrates 6.5.3 Dosage, Mode of Administration 6.5.3.1 Replacement in Children with Hemophilia A, B or von Willebrand Syndrome 6.5.3.2 Replacement in Adults with Hemophilia A, B or von Willebrand Syndrome 6.5.3.3 Indications and Recommended Doses for Treat...
full textPreparation of factor VII concentrate using CNBr-activated
Background: Factor VII concentrates are used in patients with congenital or acquired factor VII deficiency or treatment of hemophilia patients with inhibitors. In this research, immunoaffinity chromatography was used to purify factor VII from prothrombin complex (Prothrombin-Proconvertin-Stuart Factor-Antihemophilic Factor B or PPSB) which contains coagulation factors II, VII, IX and X. The a...
full textPurified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
Replacement therapy for hemophilia B (factor IX deficiency) using prothrombin complex concentrate (PCC) has been associated with serious complications of thromboembolic events and transmission of viral infections. Monoclonal antibody-purified factor IX (Mononine) provides a highly purified factor IX concentrate, while eliminating other vitamin K-dependent factors (II, VII, and X). Mononine was ...
full textSome Biochemical and Electrophoretic Studies on Purified Prothrombin , Factor VII (
S TUDIES of the chemical nature of prothrombin have indicated a glycoprotein structure.2 Data obtained on purified bovine prothrombin have shown the reducing sugar content to be approximately 5 per cent, based on a reference standard of galactose and mannose.35 Laki et al.5 reported a value of 6.5 per cent in terms of glucose, and 1.6 to 1.7 per cent hexosamine. Alexander6 and colleagues observ...
full textMy Resources
Journal title
volume 15 issue 2
pages 103- 108
publication date 2001-08
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023